Table I.
Trials of subcutaneous or intravenous unfractionated heparin in patients with acute myocardial infarction treated with thrombolytic therapy
| Trial | Treatment | N | Any death, n (%) | Reinfarction, n (%) | Any stroke, n (%) |
|---|---|---|---|---|---|
| SC heparin versus control | |||||
| ISIS-37 | SC Heparin + ASA | 20656 | 2132 (10.3) | 378 (1.9) | 261 (1.3) |
| ASA alone | 20643 | 2189 (10.6) | 414 (2.0) | 240 (1.2) | |
| GISSI-28 | SC Heparin + ASA | 10361 | 968 (9.3) | 218 (2.1) | 115 (1.1) |
| ASA alone | 10407 | 983 (9.4) | 239 (2.3) | 119 (1.1) | |
| IV heparin versus SC heparin | |||||
| GUSTO-16 | SK + IV Heparin | 10410 | 763 (7.4) | 438 (4.0) | 144 (1.4) |
| SK + SC Heparin | 9841 | 712 (7.2) | 343 (3.4) | 117 (1.2) |
SC, Subcutaneous, IV, intravenous; ASA, aspirin.